What was the proposed mechanism for the observed increases in CD11b+ and NF-κB expressing cells in GI biopsies of cats with small cell GI lymphoma and their correlation with Fusobacterium spp. numbers?

• A. CD11b+ T lymphocytes are the primary drivers of anti-tumor immunity and Fusobacterium suppresses TLR signaling.
• B. CD11b+ myeloid cells might contribute to development of a tumor microenvironment and Fusobacterium spp. might induce toll-like receptors (TLR), to stimulate NF-κB through the TLR4/MYD88 pathway.
• C. NF-κB signaling occurs independently of Fusobacterium presence.
• D. Increased Fusobacterium reduces mucosal inflammation.

Answer: (B)

The main idea here is that Fusobacterium can drive inflammation in the gut by activating innate immune cells, and this activation hinges on Toll-like receptor signaling leading to NF-κB activation. CD11b marks myeloid cells such as monocytes and macrophages, which populate the tumor microenvironment in GI lymphoma. When Fusobacterium numbers are higher, its components (notably LPS-like molecules) engage TLRs on these myeloid cells, especially TLR4, triggering the MyD88-dependent signaling pathway. This activates NF-κB, a transcription factor that turns on many inflammatory genes.

As NF-κB becomes more active, these CD11b+ cells are recruited and activated, and inflammatory mediators they produce further sustain a pro-tumor microenvironment. The observed correlation between Fusobacterium abundance and both CD11b+ and NF-κB-expressing cells fits this sequence: more bacteria provide more TLR stimulation, which boosts NF-κB activity and expands or sustains the CD11b+ myeloid cell population.

In contrast, the idea that CD11b+ cells are T lymphocytes or that Fusobacterium suppresses TLR signaling would not explain why higher Fusobacterium correlates with more NF-κB activity and more CD11b+ cell signal. Nor would it align with the notion that NF-κB activation is independent or that Fusobacterium dampens mucosal inflammation.